News sentiment analysis powered by sentiment-insight.com
Grifols lifts 2023 guidance after swinging to net...
Spanish drugmaker Grifols reported a third-quarter net profit of 60 million euros. The company lifted its 2023 guidance for adjusted earnings before interest, taxes, depreciation and amortization to 1.45 billion euros.
Grifols shares soar after 2023 profit outlook upgrade Grifols posts a third-quarter net profit of 60 million euros ($63.64 million) Company raises its 2023 guidance for adjusted earnings before interest, taxes, depreciation and amortisation to 1.45 billion euros. Shares were up 9.7% in early trading.
Grifols shares soar after 2023 profit outlook upgrade Grifols posted a third-quarter net profit of 60 million euros ($63.64 million) The company raised its 2023 guidance for adjusted earnings before interest, taxes, depreciation and amortisation to 1.45 billion euros. Its shares were up 13.4% in mid-morning trading and were on track for their best day ever.
Grifols shares soar as it discloses potential sale of... Grifols shares soar as it discloses potential sale of $1.5 bln stake in Shanghai RAAS. Shares in Grifols were rising 9.8% in early morning trading.
Grifols shares soar on possible sale of $1.5 bln stake in Shanghai RAAS Shares in Grifols were up 8.0% in morning trade after the company announced it was planning to change the shareholding structure in the Chinese company. The Spanish company said it would receive $1.5 billion if the deal goes ahead.
Grifols shares soar on possible sale of $1.5 bln stake... Shares in Grifols were up 8.0% in morning trade after the company announced it was planning to change the shareholding structure in Shanghai RAAS. The company would receive $1.5 billion if the deal goes ahead, the Spanish company said.
Grifols shares soar on possible sale of $1.5 billion stake in Shanghai RAAS Shares in Grifols were up 8.0% in morning trade after the company announced it was planning to change the shareholding structure in Shanghai RAAS. The Spanish company would receive $1.5 billion if the deal goes ahead, the Spanish company said.
Grifols shares soar on possible sale of $1.5 billion stake in Shanghai RAAS Grifols would receive $1.5 billion if the deal goes ahead, the Spanish company said. Grifols added it would keep a'significant stake' in Shanghai RAAS. The company was hit at the start of the pandemic as plasma collection was restricted.
Grifols posts higher Q1 core earnings but swings to net... Grifols posts a 19% rise in first-quarter core earnings to 299 million euros ($329.1 million) But the company still swings to a net loss of 108 million euros due to its cost-cutting plans.
Grifols posts higher Q1 core earnings but swings to net loss due to layoffs Grifols reported a 19% rise in first-quarter core earnings to 299 million euros ($329.1 million) Revenues grew 23%, but the company still swung to a net loss of 108 million euros. Spanish pharmaceutical group now estimates to save 50 million euros more.
Grifols lifts 2023 margin outlook as revenue rises Spanish drugmaker Grifols lifts its 2023 margin outlook after reporting sturdy growth in first-quarter core earnings and revenue. The company was severely hit at the start of the pandemic due to plasma shortages and left its share price three times lower than it was in 2020.
Grifols posts higher Q1 core earnings but swings to net loss due to layoffs Spanish pharmaceutical group Grifols reported a 19% rise in first-quarter core earnings to 299 million euros ($329.1 million) But the company still swung to a net loss of 108 million euros due to its cost-cutting plans.
Spain's Grifols names current chairman as CEO, ending... Spain's Grifols names current chairman as CEO, ending founding family's executive leadership. Thomas Glanzmann had served as the board's vice chairman since 2017. The Barcelona-based company was severely hit at the start of the pandemic.
Spain's Grifols names current chairman as CEO, ending family leadership Thomas Glanzmann will become Grifols' new chief executive with immediate effect. He had served as the board's vice chairman since 2017. The Barcelona-based company uses blood plasma to make medicines. It was severely hit at the start of the pandemic due to plasma shortages.
Grifols' shares tank 10% as 2023 outlook disappoints Grifols' shares were 9.6% down at 15:44 GMT and were the worst performers on the blue-chip Spanish Ibex index. Grifols reported on Tuesday that net profit rose 10% to 208 million euros ($220.19 million) Total revenues rose 23% to 6 billion euros ($6.38 billion)
Grifols' shares tank 10% as 2023 outlook disappoints Grifols' shares were 9.6% down at 15:44 GMT and were the worst performers on the blue-chip Spanish Ibex index. The Barcelona-based company, which uses blood plasma to make medicines, expects its EBITDA to rise to 1.7 billion euros in 2023.
Grifols' 2022 net profit up 10% to 208 mln euros as... Grifols' 2022 net profit up 10% to 208 mln euros as plasma collection rises. Blood plasma collection grew more than 25% after being severely hit during pandemic.
Executive chairman of Spanish pharma company Grifols resigns Steven F. Mayer has resigned as executive chairman of the board of Spanish pharmaceutical company Grifols. Thomas Glanzmann, who has served as the board's vice chairman since 2017, has been appointed as Mayer's successor.
Executive chairman of Spanish pharma company Grifols... Steven F. Mayer has resigned as executive chairman of the board of Spanish pharmaceutical company Grifols. Thomas Glanzmann, who has served as the board's vice chairman since 2017, has been appointed as Mayer's successor.
Executive chairman of Spanish pharma company Grifols... Steven F. Mayer has resigned as executive chairman of the board of Spanish pharmaceutical company Grifols. Thomas Glanzmann, who has served as the board's vice chairman since 2017, has been appointed as Mayer's successor with immediate effect.
Sign Up
